… 2 is exaggerated in the presence of concomitant obesity [78]. An … ACS [130], that therapy
with perhexiline for three days was … also occurred after perhexiline therapy in patients with SAP …

… and profile induced by cholestatic drugs in human liver. In this study, we aimed to analyze
the effects of a large set of cholestatic and noncholestatic drugs in presence of physiological …

… Subclinical or clinically evident hyposmia is a frequent concomitant feature in PAF patients
[… include the antiarrhythmic agent, amiodarone, the coronary vasodilator, perhexiline, and the …

… This case report suggests that medication therapy may not … to elucidate the mechanism of
perhexiline's toxicity in human … He was taking amiodarone and pravastatin for 1 year which …

… of diabetic dyslipidemia (DLP); antioxidants; vitamins; treatment of myocardial metabolic
abnormalities; thrombosis; management of OH; symptomatic treatment of concomitant diseases …

… Research has shown that drugs such as perhexiline, amiodarone, and tamoxifen can
accumulate in the mitochondria and can interfere with some processes including the electron …

… This type of drug toxicity occurs when two or more drugs capable of increasing serotonin
levels in nerve terminals are used concomitantly (18). A large number of drugs have “serotonin” …

… The remaining compounds consist of five agents, including three FDA-approved drugs for
cardiovascular indications, niguldipine, nicardipine and amiodarone, that inhibit intracellular …

… This dissociation event results in the dephosphorylation of inhibitory sites of Ulk1/2 and
autophosphorylation of its activating sites, which leads to concomitant activation of its interacting …

… drugs that cause steatosis and steatohepatitis independently from any concomitant
triggering factor (eg, amiodarone and perhexiline maleate); and 3. …